485 related articles for article (PubMed ID: 35122211)
1. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M
BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA; Yang YK; Zhang J; Xu K; Liang Y; Kang Y; Su JG; Yang T; Hussein S; ElDein MS; Shao S; Yang SS; Lei W; Gao XJ; Jiang Z; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Liu N; Shen FJ; Qu L; Zhang YT; Yang XM; Wu G; Li QM
Signal Transduct Target Ther; 2022 Jun; 7(1):172. PubMed ID: 35665745
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Kaabi NA; Yang YK; Du LF; Xu K; Shao S; Liang Y; Kang Y; Su JG; Zhang J; Yang T; Hussein S; ElDein MS; Yang SS; Lei W; Gao XJ; Jiang Z; Cong X; Tan Y; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Hou JW; Lei ZH; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM
Nat Commun; 2022 Jun; 13(1):3654. PubMed ID: 35760812
[TBL] [Abstract][Full Text] [Related]
6. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older.
Chen Y; Zhang X; Gong L; Liang Z; Hu X; Xing B; Liao Y; Yuan L; Chen G; Lv H
Expert Rev Vaccines; 2023; 22(1):1079-1090. PubMed ID: 37877219
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study.
Ren N; Wang Z; Gao S
Viral Immunol; 2024; 37(1):16-23. PubMed ID: 38109058
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
[TBL] [Abstract][Full Text] [Related]
10. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
Front Immunol; 2022; 13():967051. PubMed ID: 36159863
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
Toback S; Marchese AM; Warren B; Ayman S; Zarkovic S; ElTantawy I; Mallory RM; Rousculp M; Almarzooqi F; Piechowski-Jozwiak B; Bonilla MF; Bakkour AE; Hussein SE; Al Kaabi N
Vaccine; 2024 Mar; 42(7):1777-1784. PubMed ID: 38365482
[TBL] [Abstract][Full Text] [Related]
13. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Kaabi NA; Yang YK; Liang Y; Xu K; Zhang XF; Kang Y; Jin YQ; Hou JW; Zhang J; Yang T; Hussein S; ElDein MS; Lei ZH; Zhang H; Shao S; Liu ZM; Liu N; Zheng X; Su JG; Yang SS; Cong X; Tan Y; Lei W; Gao XJ; Jiang Z; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Xiao P; Shen FJ; Wu JJ; Han ZB; Du LF; Tang F; Chen S; Ma ZJ; Zheng F; Hou YN; Li XY; Li X; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM
Signal Transduct Target Ther; 2023 Jan; 8(1):20. PubMed ID: 36596779
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A
Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
Terada-Hirashima J; Takamatsu Y; Shimizu Y; Uemura Y; Takeuchi JS; Tomita N; Matsuda K; Maeda K; Yamamoto S; Fukunaga A; Ohmagari N; Mikami A; Sonoda K; Ujiie M; Mitsuya H; Sugiura W
Hum Vaccin Immunother; 2023 Dec; 19(1):2193074. PubMed ID: 37052247
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
Huang T; Hu Q; Zhou X; Yang H; Xia W; Cao F; Deng M; Teng X; Ding F; Zhong Z; Gao L; Sun J; Gong L
BMC Infect Dis; 2024 Apr; 24(1):413. PubMed ID: 38641791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
